EPHX2 and heart failure: Inhibitors of sEH afford broad cardiovascular protection, including blockade of smooth muscle proliferation [14], reduction of atherosclerosis and hypertension [[15], [16], [17], [18], [19], [20]], prevention and regression of hypertrophy and heart failure [[21], [22], [23]], as well as limiting cardiac fibrosis [24].